ReviewJournal of mammary gland biology and neoplasia2008
Regulation of prolactin receptor levels and activity in breast cancer.
Review in Journal of mammary gland biology and neoplasia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence.Frontiers in oncology · 2022Pooled it
- Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review.International cancer conference journal · 2025Article
- Dopamine D2 receptor antagonist counteracts hyperglycemia and insulin resistance in diet-induced obese male mice.PloS one · 2024Article
- Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma.Stem cells international · 2023Article
- Prolactin and its significance in the placenta.Hormones (Athens, Greece) · 2022Review
- The effect of prolactin on immune cell subsets involved in SLE pathogenesis.Frontiers in immunology · 2022Review
- Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.Journal of cellular and molecular medicine · 2021Review
- Gene expression profiles for low-dose exposure to diethyl phthalate in rodents and humans: a translational study with implications for breast carcinogenesis.Scientific reports · 2020Article
- Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1.Cancer research · 2016Article
- PAK1 translocates into nucleus in response to prolactin but not to estrogen.Biochemical and biophysical research communications · 2016Article
- Seasonal Expression of Prolactin Receptor in the Scented Gland of Male Muskrat (Ondatra zibethicus).Scientific reports · 2015Article
- New insights in prolactin: pathological implications.Nature reviews. Endocrinology · 2015Review
- Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.Advances in experimental medicine and biology · 2015Article
- Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling.Frontiers in endocrinology · 2015Article
- Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.PloS one · 2015Article
- Article
- Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.Mayo Clinic proceedings · 2014Review
- Breast cancer: the menacing face of Janus kinase.Cell death and differentiation · 2014Article
- Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.Journal of cellular biochemistry · 2014Review
- Miz1 deficiency in the mammary gland causes a lactation defect by attenuated Stat5 expression and phosphorylation.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
From its traditional identity as a hormone involved in growth and differentiation of mammary epithelium and in lactation, to having a pertinent role in the development of mammary carcinoma, the peptide hormone/cytokine prolactin (PRL) has emerged as a versatile signaling molecule. There has been significant progress in our understanding of the fine working of PRL in the past several years. Notably, much effort has been concentrated on the mediator of PRL action, namely, the prolactin receptor (PRLr). The causal link between increased PRLr expression and breast cancer is being increasingly appreciated. Considering that the level of the receptor on the surface is a critical determinant of signaling output in response to PRL, the uncovering of regulatory elements that control receptor expression becomes important. The principle focus of this review is on the regulation of PRLr expression and activity in breast cancer with a brief overview of different isoforms of PRLr, their expression, signaling capabilities and the biological outcomes of PRL/PRLr signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.